PARSIPPANY, N.J., July 26, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue of $1.1 billion for the second quarter ended June 30, 2011, an increase of 24 percent when compared to $875.3 million in the second quarter 2010. On a non-GAAP basis, net income for the second quarter 2011 increased 24 percent to $127.9 million or $1.01 per share, compared to $102.8 million or $0.83 per share in the second quarter 2010. GAAP diluted earnings per share for the second quarter 2011 were $0.42, compared to $0.57 in the prior year period. Watson's results for the second quarter include the results of Specifar Pharmaceuticals since its acquisition on May 25, 2011. Refer to the attached reconciliation tables for adjustments to GAAP earnings.
For the second quarter 2011, adjusted EBITDA increased 17 percent to $243.3 million, compared to $207.4 million for the second quarter 2010. Cash and marketable securities were $234.0 million as of June 30, 2011.
"Our record $1 billion in net revenues in the second quarter demonstrates the strength of our combined Global Generics and Global Brands strategies. Our May 2nd launch of methylphenidate ER added significant additional earnings power to our strong, sustained release base business and, combined with the expansion of our international generics business, delivered 39 percent growth in Global Generics net revenues. Net revenue growth of 9 percent in our Global Brands business, powered by the addition of new products including Crinone® and Generess™ Fe and increased sales of RAPAFLO®, demonstrated that this segment of our business continues to execute on its 2011 plan," said Paul Bisaro, President and CEO.
"We continued to invest in the growth of our Global Generics business, increasing our R&D investment by 31 percent in the quarter, as well as ity investments
0.894.6Proceeds from sale of marketable securities
2.97.3Additions to marketable securities
(1.5)(4.3)Additions to long-term investments
-(17.1)Other investing activities, net
0.61.0Net cash (used in) provided by investing activities
(609.2)43.4CASH FLOWS FROM FINANCING ACTIVITIES:Principal payments on debt and other long-term liabilities
-(4.3)Principal payments on revolving loan and acquired debt
(28.8)(220.0)Proceeds from borrowings on credit facility
250.0-Repurchase of common stock
(11.1)(4.6)Acquisition of noncontrolling interest
(5.5)-Proceeds from stock plans
42.625.5Excess tax benefit from stock-based compensation
9.9-Net cash provided by (used in) financing activities
257.1(203.4)Effect of currency exchange rate changes on cash and cash equivalents
2.6(2.7)Net increase in cash and cash equivalents
(57.7)23.4Cash and cash equivalents at beginning of period
282.8201.4Cash and cash equivalents at end of period
224.8The following table presents a reconciliation of reported net income and diluted earnings per share to non-GAAP net income for the three and six months ended June 30, 2011 and 2010:
Table 4Watson Pharmaceuticals, Inc.Reconciliation Table(Unaudited; in millions except per share amounts)Three Months EndedJune 30,Six Months EndedJune 30,2011201020112010GAAP to non-GAAP net income calculationReported GAAP net income attributable to
74.943.1132.082.1Global supply chain initiative(1)
3.515.512.120.7Acquisition and licensing charges
8.72.013.321.4Interest accretion on contingent liabilities
9.86.818.813.4Non-cash impairment charges
220.127.116.11.1Other (gains) losses
---3.0Income taxes on items above
(27.6)(33.9)(49.0)(54.2)Non-GAAP net income attributable to
203.1Diluted earnings per share Diluted earnings per share - GAAP
.14Diluted earnings per share - Non-GAAP
.64Basic weighted average common shares outstanding
124.5122.3124.1122.0Effect of dilutive securities: Dilutive share-based compensation arrangements
1.91.72.01.7Diluted weighted average common shares outstanding
126.4124.0126.1123.7(1) Includes accelerated depreciation charges. The following table presents a reconciliation of reported net income to adjusted EBITDA for the three and six months ended June 30, 2011 and 2010:
Table 5Watson Pharmaceuticals, Inc.Adjusted EBITDA Reconciliation Table(Unaudited; in millions)Three Months EndedJune 30,Six Months EndedJune 30,2011201020112010GAAP net income attributable to common shareholders$
40.4Plus:Interest expense22.920.044.740.3Interest income(0.5)(0.3)(1.3)(0.7)Provision for income taxes43.227.984.564.6Depreciation (includes accelerated depreciation)25.726.648.751.3Amortization74.943.1132.082.1EBITDA218.9187.9406.6378.0Adjusted for:Global supply chain initiative2.012.78.516.5Acquisition and licensing charges18.104.22.1681.5Non-cash impairment charges22.214.171.124.1Other (gains) losses(1.5)(1.4)(7.2)(24.8)Legal settlements---3.0Share-based compensation7.86.016.211.0Adjusted EBITDA$
406.3The following table presents a reconciliation of forecasted net income for the twelve months ending December 31, 2011 to non-GAAP net income and non-GAAP earnings per diluted share:
Table 6Watson Pharmaceuticals, Inc.Reconciliation Table (Unaudited; in millions except per share amounts)Forecast for Twelve MonthsEnding December 31, 2011LowHighGAAP to non-GAAP net income calculationGAAP net income
317317Global supply chain initiative
1616Acquisition and licensing charges
3434Interest accretion on contingent liabilities
3939Non-cash impairment charges
2525Other (gains) losses
(7)(7)Income taxes on items above
(112)(112)Non-GAAP net income
538570Diluted earnings per shareDiluted earnings per share - GAAP
2.04Diluted earnings per share - Non-GAAP
4.50Diluted weighted average common shares outstanding
126.7126.7The reconciliation table is based in part on management's estimate of non-GAAP net income for the year ending December 31, 2011. Watson expects certain known GAAP charges for 2011, as presented in the schedule above. Other GAAP charges that may be excluded from non-GAAP net income are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown. These GAAP charges are dependent upon future events and valuations that have not yet been performed.
The following table presents a reconciliation of forecasted net income for the twelve months ending December 31, 2011 to adjusted EBITDA:
Table 7Watson Pharmaceuticals, Inc.Reconciliation Table - Forecasted Adjusted EBITDA(Unaudited; in millions)Forecast for Twelve MonthsEnding December 31, 2011LowHighGAAP net income
(1)(1)Provision for income taxes
199217Depreciation (includes accelerated depreciation)
931981Adjusted for:Global supply chain initiative
1111Acquisition and licensing charges
3434Non-cash impairment charges
2525Other (gains) losses
,075The reconciliation table is based in part on management's estimate of adjusted EBITDA for the year ending December 31, 2011. Watson expects certain known GAAP charges for 2011, as presented in the schedule above. Other GAAP charges that may be excluded from estimated EBITDA are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown. These GAAP charges are dependent upon future events and valuations that have not yet been performed.
Watson Pharmaceuticals, Inc.Patty Eisenhaur(862) 261-8141Charlie Mayr(862) 261-8030 in our Global Brands business, with R&D spending up 29 percent. We also announced our acquisition of Specifar Pharmaceuticals, which brings not only additional earnings contribution, but also an expanded international platform for generic growth opportunities. In our Brand business, we announced an anticipated FDA action date for PROCHIEVE®, and shortly after the end of the quarter, entered into an exclusive licensing agreement with Antares Pharma, Inc. for a product that, if approved, will expand our position in the over-active bladder (OAB) market segment."
"We concluded the quarter with $245.0 million in borrowing capacity available on our revolving credit facility and our debt to adjusted EBITDA ratio remains favorable at 1.4x, affording us the ability to continue to pursue opportunities to expand Watson's businesses," concluded Bisaro.
Business Segment ResultsGlobal Generics Segment InformationThree Months EndedJune 30,Six Months EndedJune 30,(Unaudited; $ in millions)
792.4571.01,392.51,114.8Operating expenses:Cost of sales
439.1305.9728.2593.4Research and development
58.344.6112.786.8Selling and marketing
32.5%33.8%34.7%34.1%Adjusted gross profit (1)
550.4Adjusted gross margin
45.2%48.6%48.0%49.4%(1) Adjusted gross profit represents adjusted net revenue less adjusted cost of sales and excludes amortization of acquired intangibles. Pro forma adjustments for the respective periods include the following: Settlement of contingent asset acquired as part of a business combination
-Operational Excellence Initiative
1.912.25.317.2Purchase accounting adjustments
2.7-2.711.8Global Generics net revenue for the second quarter 2011 increased 39 percent to $792.4 million due to increased sales of extended-release products, primarily as a result of the launch of methylphenidate ER during the quarter. Extended release product sales were $380.1 million, up 138 percent from the second quarter 2010 as a result of the launch of methylphenidate ER and higher sales of metoprolol succinate ER. Second quarter international net revenue was $119.2 million, up eight percent from the second quarter 2010, as a result of the addition of Specifar Pharmaceuticals in May.
Global Generics adjusted gross margin decreased 3.4 percentage points to 45.2 percent in the second quarter 2011. Adjusted Global Generics gross margin was negatively impacted by the launch of methylphenidate ER.
Global Generics R&D investment for second quarter 2011 increased 31 percent to $58.3 million, primarily due to increased clinical study costs and increased investment in international R&D. Six new products were launched in the U.S. and we had seven new patent challenges during the quarter.
Global Brands Segment InformationThree Months EndedJune 30,Six Months EndedJune 30,(Unaudited; $ in millions)
112.9103.5209.8194.8Operating expenses:Cost of sales
25.123.642.948.3Research and development
126.96.36.199.5Selling and marketing
77.8%77.2%79.6%75.2%Global Brands net revenue increased nine percent to $112.9 million in the second quarter 2011 as a result of the addition of new products including Crinone®, Generess™ Fe and Nulecit™ and increased sales of RAPAFLO®. Global Brands other revenue decreased $5.7 million to $20.9 million. Other revenue in the second quarter of 2010 was favorably impacted by the out-licensing of two legacy brand products.
Gross margin for the Global Brands segment increased 0.6 percentage points to 77.8 percent.
Global Brands R&D investment increased 29 percent to $22.2 million in the second quarter 2011 as a result of increased biosimilar R&D investment, clinical study and other costs. Global Brands announced the submission of a New Drug Application (NDA) for PROCHIEVE® with expected FDA action in February of 2012, launched a new oral contraceptive Generess™ Fe and announced new research for RAPAFLO®, highlighting its ability to reduce symptoms of moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), potentially expanding the reach for this important product. Following the close of the quarter, the group also announced an exclusive licensing agreement with Antares Pharma, Inc. to commercialize its topical oxybutynin gel product in the U.S. and Canada.
Distribution Segment InformationThree Months EndedJune 30,Six Months EndedJune 30,(Unaudited; $ in millions)
422.2Operating expenses:Cost of sales
149.2168.5297.9361.0Selling and marketing
15.4%16.1%16.3%14.5%Distribution segment net revenue for the second quarter 2011 decreased 12 percent to $176.4 million, due to fewer third-party product launches in the quarter. Distribution revenue consists only of sales of third-party products.
Distribution segment gross margin was 15.4 percent in the second quarter 2011.
Other Operating ExpensesConsolidated general and administrative expenses were $85.4 million in the second quarter 2011, an increase of $9.5 million from the second quarter 2010, which includes $6.0 million in costs associated with the acquisition of Specifar. Amortization expense for the second quarter 2011 was $74.6 million, compared to $43.1 million in second quarter 2010, reflecting higher amortization rates in our international business and accelerated amortization of Nulecit™ product rights due to market conditions.
2011 Financial Outlook Watson's estimates are based on actual results for the second quarter 2011 and management's current belief about prescription trends, pricing levels, inventory levels and the anticipated timing of future product launches and events.
Webcast and Conference Call DetailsWatson will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time to discuss second quarter 2011 results, the outlook for the remainder of the year and recent corporate developments. The dial-in number to access the call is (877) 251-7980, or from international locations, (706) 643-1573. A taped replay of the call will be available by calling (800) 642-1687 with access pass code 79602222. The replay may be accessed from international locations by dialing (706) 645-9291 and using the same pass code. This replay will remain in effect until midnight Eastern Daylight Time, August 9, 2011. To access the live webcast, go to Watson's Investor Relations Web site at http://ir.watson.com.
About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc., is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.
For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.
Forward-Looking StatementStatements contained in this press release that refer to Watson's estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Watson's strategic initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Watson's goals and expectations are not predictions of actual performance. Watson's performance, at times, will differ from its goals and expectations. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the inherent uncertainty associated with financial projections; the impact of competitive products and pricing; timely and successful consummation of strategic transactions; the difficulty of predicting the timing or outcome of litigation; successful integration of strategic transactions including the acquisition of Specifar Pharmaceuticals; the ability to recognize the anticipated synergies and benefits of strategic transactions; variability of revenue mix between the Company's Brand, Generic and Distribution business units; periodic dependence on a small number of products for a material source of net revenue or income; variability of trade buying patterns; fluctuations in foreign currency exchange rates; changes in generally accepted accounting principles; risks that the carrying values of assets may be negatively impacted by future events and circumstances; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the uncertainty associated with the identification and successful consummation of external business development transactions; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson's and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare, Medicaid, and similar laws in foreign countries affecting, among other things, pricing and reimbursement of pharmaceutical products and the settlement of patent litigation; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the period ended December 31, 2010 and Watson's quarterly report on Form 10-Q for the period ended March 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.
All trademarks are the property of their respective owners.
The following table presents Watson's results of operations for the three and six months ended June 30, 2011 and 2010:
Table 1WATSON PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited; in millions, except per share amounts)Three Months EndedJune 30,Six Months EndedJune 30,2011201020112010Net revenues
,731.8Operating expenses:Cost of sales (excludes amortization, presented below)
613.4498.01,069.01,002.7Research and development
80.561.8154.8121.3Selling, general and administrative
74.643.1131.282.1Loss on asset sales and impairments
188.8.131.52.1Total operating expenses
118.3115.7229.1216.0Non-operating income (expense):Interest income
(0.3)2.5(4.0)28.6Total other income (expense), net
(22.7)(17.2)(47.4)(11.0)Income before income taxes and noncontrolling interest
95.698.5181.7205.0Provision for income taxes
52.470.697.2140.4Loss attributable to noncontrolling interest
0.3-0.8-Net income attributable to common shareholders
40.4Earnings per share:Basic
.14Weighted average shares outstanding:Basic
126.4124.0126.1123.7The following table presents Watson's Condensed Consolidated Balance Sheets as of June 30, 2011 and December 31, 2010:
Table 2WATSON PHARMACEUTICALS, INC.Condensed Consolidated Balance Sheets(Unaudited; in millions)June 30,2011December 31,2010AssetsCash and cash equivalents
8.911.1Accounts receivable, net
627.8631.0Other current assets
319.3313.6Property and equipment, net
690.0642.3Investments and other assets
249.6225.5Product rights and other intangibles, net
5,827.3Liabilities & EquityCurrent liabilities
1,024.51,016.1Deferred income taxes and other liabilities
3,473.43,282.6Total liabilities and equity
5,827.3The following table presents Watson's Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2011 and 2010:
Table 3WATSON PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited; in millions)Six Months EndedJune 30,20112010CASH FLOWS FROM OPERATING ACTIVITIES:Net income
40.4Reconciliation to net cash provided by operating activities:Depreciation
131.282.1Deferred income tax (benefit) provision
(43.9)(26.9)Provision for inventory reserve
26.621.1Share based compensation
16.211.0(Earnings) losses on equity method investments
5.1(3.3)(Gain) loss on securities
(0.8)(24.8)Accretion of discount on preferred stock and contingent consideration obligation
23.413.3Loss on asset sales and impairments
21.80.2Excess tax benefit from stock-based compensation
0.32.0Changes in assets and liabilities:Accounts receivable, net
9.0(45.5)Prepaid expenses and other current assets
2.7(6.8)Accounts payable and accrued expenses
(4.3)(2.6)Income and other taxes payable
(8.2)(23.6)Other assets and liabilities
(4.9)(0.4) Total adjustments
194.645.7Net cash provided by operating activities
291.8186.1CASH FLOWS FROM INVESTING ACTIVITIES:Additions to property and equipment
(41.5)(16.5)Acquisition of product rights
(10.2)(7.1)Acquisition of business, net of cash acquired
(561.1)(16.8)Proceeds from sale of fixed assets
0.82.3Proceeds from sale of cost/equ
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved